Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C8H13N5O4.ClH |
Molecular Weight | 279.6811 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C([C@]1([H])[C@]([H])([C@]([H])([C@]([H])(n2cnc(C(=N)N)n2)O1)O)O)O.Cl
InChI
InChIKey=PIGYMBULXKLTCJ-UHSSARMYSA-N
InChI=1S/C8H13N5O4.ClH/c9-6(10)7-11-2-13(12-7)8-5(16)4(15)3(1-14)17-8;/h2-5,8,14-16H,1H2,(H3,9,10);1H/t3-,4-,5-,8-;/m1./s1
Molecular Formula | ClH |
Molecular Weight | 36.4609 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C8H13N5O4 |
Molecular Weight | 243.2203 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Taribavirin, an oral prodrug of ribavirin that was developed as nucleoside antimetabolite, which interferes with duplication of viral genetic material. Taribavirin was studied in phase III clinical trial for the treatment of chronic hepatitis C patients. However, this drug not yet approved for pharmaceutical use.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis and antiviral activity of 1,2,4-triazole-3-thiocarboxamide and 1,2,4-triazole-3-carboxamidine ribonucleosides. | 1973 Aug |
|
Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced Phlebovirus infections. | 1988 Dec 1 |
|
Treatment of lethal Pichinde virus infections in weanling LVG/Lak hamsters with ribavirin, ribamidine, selenazofurin, and ampligen. | 1993 Jan |
|
Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections. | 1994 Oct |
|
A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus. | 2004 Apr |
|
Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin. | 2004 Oct |
|
Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. | 2007 Jul |
|
Therapeutic issues in HIV/HCV-coinfected patients. | 2007 Jun |
|
Taribavirin for the treatment of chronic hepatitis C. | 2008 Dec |
|
Ribavirin analogs. | 2009 Aug |
|
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results. | 2009 Sep |
|
New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents. | 2010 |
|
Hepatitis C and kidney disease. | 2010 |
|
Antiviral therapy for hepatitis C virus: beyond the standard of care. | 2010 Apr |
|
Hepatitis C treatment: current and future perspectives. | 2010 Nov 1 |
|
The next step for taribavirin. | 2010 Oct |
|
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. | 2010 Oct |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00230958
viramidine (TARIBAVIRIN) 600 mg BID
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 05:51:46 UTC 2021
by
admin
on
Sat Jun 26 05:51:46 UTC 2021
|
Record UNII |
D22JZE246P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C281
Created by
admin on Sat Jun 26 05:51:46 UTC 2021 , Edited by admin on Sat Jun 26 05:51:46 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C77929
Created by
admin on Sat Jun 26 05:51:46 UTC 2021 , Edited by admin on Sat Jun 26 05:51:46 UTC 2021
|
PRIMARY | |||
|
DBSALT002011
Created by
admin on Sat Jun 26 05:51:46 UTC 2021 , Edited by admin on Sat Jun 26 05:51:46 UTC 2021
|
PRIMARY | |||
|
40372-00-7
Created by
admin on Sat Jun 26 05:51:46 UTC 2021 , Edited by admin on Sat Jun 26 05:51:46 UTC 2021
|
PRIMARY | |||
|
SUB21031
Created by
admin on Sat Jun 26 05:51:46 UTC 2021 , Edited by admin on Sat Jun 26 05:51:46 UTC 2021
|
PRIMARY | |||
|
M10467
Created by
admin on Sat Jun 26 05:51:46 UTC 2021 , Edited by admin on Sat Jun 26 05:51:46 UTC 2021
|
PRIMARY | Merck Index | ||
|
451447
Created by
admin on Sat Jun 26 05:51:46 UTC 2021 , Edited by admin on Sat Jun 26 05:51:46 UTC 2021
|
PRIMARY | |||
|
D22JZE246P
Created by
admin on Sat Jun 26 05:51:46 UTC 2021 , Edited by admin on Sat Jun 26 05:51:46 UTC 2021
|
PRIMARY | |||
|
CHEMBL2111108
Created by
admin on Sat Jun 26 05:51:46 UTC 2021 , Edited by admin on Sat Jun 26 05:51:46 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |